Suppliers / Aino Co., Ltd.of North China Pharmaceutical Group

Aino Co., Ltd.of North China Pharmaceutical Group

China Updated 9 July 2026

The public registers hold a second record for Aino Co., Ltd.of North China Pharmaceutical Group. The fuller profile, with 9 active US DMFs and 5 valid CEPs, is at North China Pharmaceutical. Figures on this page cover only this record.

Aino Co., Ltd.of North China Pharmaceutical Group is an API manufacturer based in China. It holds one valid CEP. Its most recent recorded inspection, by US FDA, closed on 17 January 2019 as VAI.

0
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 17 January 2019 VAI US FDA
  • 29 April 2016 VAI US FDA
  • 18 November 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3004090057
Shijiazhuang, China Not on file

What they file, and where

Molecule Regulators Docs
Ivermectin EDQM 1

Also appears on these molecule pages

Ivermectin API

Questions about Aino Co., Ltd.of North China Pharmaceutical Group

Does Aino Co., Ltd.of North China Pharmaceutical Group hold a US DMF or a CEP?
Aino Co., Ltd.of North China Pharmaceutical Group holds 1 valid CEP. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Aino Co., Ltd.of North China Pharmaceutical Group FDA-registered?
One site operated by Aino Co., Ltd.of North China Pharmaceutical Group carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Aino Co., Ltd.of North China Pharmaceutical Group's last inspection go?
The most recent inspection on record closed on 17 January 2019 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Aino Co., Ltd.of North China Pharmaceutical Group manufacture?
2 registered sites are on record, in China (China and Shijiazhuang). Every site is listed on this page with the register it came from.
What does Aino Co., Ltd.of North China Pharmaceutical Group make?
1 molecule is on record against Aino Co., Ltd.of North China Pharmaceutical Group, including Ivermectin. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Aino Co., Ltd.of North China Pharmaceutical Group comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 17 January 2019.

Comparable suppliers

Industriale Chimica shares 1 molecule Hisun Pharmaceutical shares 1 molecule Hovione PharmaScience shares 1 molecule Chemo Biosynthesis shares 1 molecule Hebei Meihe Pharmaceutical shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability